EcoDrugPlus

Sodium Voltage-Gated Channel Alpha Subunit 10

Ensembl ID : ENSSARG00000004022
Gene Symbol: SCN10A
1 External references
297 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 2

Ensembl ID : ENSSARG00000002229
Gene Symbol: SCN2A
1 External references
130 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 3

Ensembl ID : ENSSARG00000003954
Gene Symbol: SCN3A
1 External references
167 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 7

Ensembl ID : ENSSARG00000003315
Gene Symbol: SCN7A
1 External references
86 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSSARG00000001540
Gene Symbol: SCN8A
1 External references
274 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 9

Ensembl ID : ENSSARG00000010873
Gene Symbol: SCN9A
1 External references
110 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSSARG00000009479
Gene Symbol: SLC10A2
1 External references
214 Possible Orthologues:

Solute Carrier Family 18 Member A2

Ensembl ID : ENSSARG00000001964
Gene Symbol: SLC18A2
1 External references
223 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSSARG00000013731
Gene Symbol: SLC5A1
1 External references
250 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSSARG00000004357
Gene Symbol: SLC6A4
3 External references
204 Possible Orthologues:

Sphingosine Kinase 2

Ensembl ID : ENSSARG00000005249
Gene Symbol: SPHK2
1 External references
209 Possible Orthologues:

Sphingosine-1-Phosphate Receptor 1

Ensembl ID : ENSSARG00000013468
Gene Symbol: S1PR1
1 External references
200 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).